TTAC-0001 and Pembrolizumab Phase Ib Combination Trial in Metastatic Triple-negative Breast Cancer
This is a phase 1b, open-Label clinical trial to determine the safety and tolerability and to establish a preliminary recommended Phase 2 dose (RP2D) of TTAC-0001 administered in combination with pembrolizumab in patients with metastatic triple-negative breast cancer.
Triple Negative Breast Cancer
DRUG: TTAC-0001 and pembrolizumab combination
Dose limiting toxicities, The frequency and percentage of DLT will be presented by dose level, During the first cycle (every cycle is 21 days) of treatment|Adverse events, The frequency and percentage of AEs will be presented by dose level, From date of screening visit until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years|Immunogenicity, Presence anti-drug antibody (ADA) will be listed, From date of screening visit until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years
Overall response rate, complete response (CR) or partial response (PR) by RECIST criteria, At every 2nd cycles until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years (every cycle is 21 days)]|Disease control rate, complete response (CR), partial response (PR) or stable disease (SD) by RECIST criteria, At every 2nd cycles until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years (every cycle is 21 days)|Progression free survival, Period from the date of the drug administration to the disease progression time point, From date of screening visit until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years|Overall survival, Period from the date of the drug administration to the patient's death, From date of screening visit until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years
Pharmacokinetic parameters - Cmax, Maximum concentration of drug by dose level, From date of screening visit until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years|Pharmacokinetic parameters - Cmin, Minimum concentration of drug by dose level, From date of screening visit until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years|Pharmacokinetic parameters - AUC0-t, Area under the curve from baseline to each timepoint by dose level, From date of screening visit until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years|Pharmacokinetic parameters - Tmax, Time of Cmax by dose level, From date of screening visit until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years|Pharmacokinetic parameters - CL, Clearance by dose level, FFrom date of screening visit until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years|Pharmacokinetic parameters - Vd, Volume of distribution by dose level, From date of screening visit until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years|Pharmacokinetic parameters - Ke, Elimination rate constant by dose level, From date of screening visit until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years|Pharmacokinetic parameters - TÂ½, Half-life by dose level, From date of screening visit until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years|Change in concentration of serum angiogenic factor or receptor, VEGF, placental growth factor \[PLGF\], soluble vascular endothelial growth factor receptor \[sVEGFR\]-2, sVEGFR-1, etc., From date of screening visit until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years|PD-L1, VEGFR-2 expression level, PD-L1, VEGFR-2 expression level in tumour environment such as tumour, tumour vessel and parenchymal tissue, From date of screening visit until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years
This is a phase 1b, open-Label clinical trial to determine the safety and tolerability and to establish a preliminary recommended Phase 2 dose (RP2D) of TTAC-0001 administered in combination with pembrolizumab in patients with metastatic triple-negative breast cancer.